prostate cancer

FDA clears narrow use of Lynparza in prostate cancer, continuing ‘shift’ on PARP drugs
FDA clears narrow use of Lynparza in prostate cancer, continuing ‘shift’ on PARP drugs
BioPharma Dive
AstraZeneca
Merck
Lynparza
prostate cancer
FDA
Flag link:
This Startup Just Raised $90M To Fight Cancer
This Startup Just Raised $90M To Fight Cancer
Crunchbase
Convergent Therapeutics
funding
oncology
radiopharmaceuticals
prostate cancer
Flag link:
Pfizer, Astellas' Xtandi combo cuts risk of death by 58% in prostate cancer patients
Pfizer, Astellas' Xtandi combo cuts risk of death by 58% in prostate cancer patients
Seeking Alpha
Pfizer
Astellas
Xtandi
prostate cancer
clinical trials
Flag link:
Immunic punts psoriasis, prostate cancer programs to narrow focus onto multiple sclerosis, celiac disease
Immunic punts psoriasis, prostate cancer programs to narrow focus onto multiple sclerosis, celiac disease
Fierce Biotech
Immunic
prostate cancer
psoriasis
MS
multiple sclerosis
celiac disease
Flag link:
US again spurns march-in campaign to slash cost of Pfizer, Astellas' Xtandi
US again spurns march-in campaign to slash cost of Pfizer, Astellas' Xtandi
Fierce Pharma
Pfizer
Astellas
Xtandi
prostate cancer
drug pricing
NIH
march-in rights
Flag link:
Pfizer and Astellas report positive data from prostate cancer therapy trial
Pfizer and Astellas report positive data from prostate cancer therapy trial
Clinical Trials Arena
Pfizer
Astellas
prostate cancer
clinical trials
Enzalutamide
leuprolide
Flag link:
Novartis takes step toward expanding supply of in-demand cancer drug
Novartis takes step toward expanding supply of in-demand cancer drug
Biopharma Dive
Novartis
Pluvicto
prostate cancer
Flag link:
AstraZeneca, Merck's Lynparza to face FDA panel in prostate cancer bid as PARP scrutiny escalates
AstraZeneca, Merck's Lynparza to face FDA panel in prostate cancer bid as PARP scrutiny escalates
Fierce Pharma
AstraZeneca
Merck
Lynparza
FDA
prostate cancer
Flag link:
Merck reports two Phase 3 study misses for Keytruda
Merck reports two Phase 3 study misses for Keytruda
BioPharma Dive
Merck
clinical trials
Keytruda
prostate cancer
lung cancer
Flag link:
J&J wins EU backing for PARP combo Akeega in prostate cancer—but only in some patients
J&J wins EU backing for PARP combo Akeega in prostate cancer—but only in some patients
Fierce Pharma
JNJ
Akeega
prostate cancer
PARP inhibitors
Flag link:
ASCO GU: Pfizer touts Talzenna's strong showing in PARP prostate cancer battle with AstraZeneca, J&J
ASCO GU: Pfizer touts Talzenna's strong showing in PARP prostate cancer battle with AstraZeneca, J&J
Fierce Pharma
ASCO GU
Pfizer
Astellas
Xtandi
prostate cancer
Flag link:
After several flops, Merck exec stands by aggressive Keytruda prostate cancer program
After several flops, Merck exec stands by aggressive Keytruda prostate cancer program
Fierce Biotech
Merck
Keytruda
prostate cancer
Flag link:
Roche Abandons AKT Prostate Cancer Asset
Roche Abandons AKT Prostate Cancer Asset
BioSpace
Roche
AKT inhibitors
Ipatasertib
clinical trials
castration-resistant prostate cancer
prostate cancer
Flag link:
A Hit and a Miss for Merck’s Keytruda
A Hit and a Miss for Merck’s Keytruda
BioSpace
Merck
Keytruda
prostate cancer
biliary tract cancer
Flag link:
AstraZeneca, Merck go multilingual for prostate cancer push
AstraZeneca, Merck go multilingual for prostate cancer push
Medical Marketing and Media
AstraZeneca
Merck
pharma marketing
prostate cancer
Flag link:
BioXcel, keeping cards close to its chest, teases phase 2 Keytruda combination trial data drop
BioXcel, keeping cards close to its chest, teases phase 2 Keytruda combination trial data drop
Fierce Biotech
BioXcel Therapeutics
clinical trials
Keytruda
BXCL701
prostate cancer
Flag link:
Lawmakers again urge the Biden administration to use federal law to widen access to a cancer drug
Lawmakers again urge the Biden administration to use federal law to widen access to a cancer drug
Stat
cancer
oncology
Joe Biden
Astellas
Xtandi
prostate cancer
Flag link:
JPM23: Bayer hikes sales targets for Kerendia, Nubeqa to $3B each
JPM23: Bayer hikes sales targets for Kerendia, Nubeqa to $3B each
Fierce Pharma
Bayer
JPMHC 2023
Kerendia
prostate cancer
Nubeqa
Flag link:
AstraZeneca, Merck's Lynparza wins EU nod in advanced prostate cancer right after FDA delay
AstraZeneca, Merck's Lynparza wins EU nod in advanced prostate cancer right after FDA delay
Fierce Pharma
AstraZeneca
Merck
Lynparza
Europe
prostate cancer
advanced prostate cancer
Flag link:
In Face of Multiple Patent Cliffs, Novartis' Prostate Cancer Drug Shows Promise
In Face of Multiple Patent Cliffs, Novartis' Prostate Cancer Drug Shows Promise
BioSpace
Novartis
prostate cancer
Pluvicto
clinical trials
patents
patent cliff
Flag link:

Pages